PIK3CA and neoplasm: Significantly poorer outcomes were observed for patients with PIK3CA mutated tumours as compared to patients with PIK3CA wild-type tumours (HR 2.0, 95% CI 1.0–3.9, p = 0.045) (Figure 5) although this did not remain significant in a multivariate analysis adjusting for clinicopathologic variables (Table 3).